Table 2 Therapeutic clinical trials for COVID-19 and COVID-19-associated ARDS
From: Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
NCT number | title | status | Condition or disease | Intervention/treatment | Phase | Sponsor |
|---|---|---|---|---|---|---|
NCT04292730 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | Completed | COVID-19 | Drug: Remdesivir Drug: Standard of Care | 3 | Gilead Sciences |
NCT04610541 | REMdesivir-HU Clinical Study and Severe Covid-19 Patients | Active, not recruiting | COVID-19 | Drug: Remdesivir-HU | 3 | University of Pecs |
NCT04600999 | Clinical Trial of Favipiravir Treatment of Patients With COVID-19 | Recruiting | COVID-19 | Drug: Favipiravir | 3 | University of Pecs |
NCT04276688 | Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | Completed | COVID-19 | Drug: Lopinavir/ritonavir Drug: Ribavirin Drug: Interferon Beta-1B | 2 | The University of Hong Kong |
NCT04476992 | Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement (NICOR) | Active, not recruiting | Hypoxemia Pneumonia, COVID-19 | Drug: Nitric Oxide-Sessions Drug: Nitric Oxide-Continuous and Sessions | 1 2 | Federal State Budgetary Scientific Institution, Research Institute of Cardiology |
NCT04306393 | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 (NOSARSCOVID) | Active, not recruiting | COVID-19 | Drug: Nitric Oxide Gas | 2 | Massachusetts General Hospital |
NCT04478071 | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Recruiting | Covid19 ARDS | Drug: vadadustat Drug: placebo | 2 | The University of Texas Health Science Center, Houston |
NCT04653831 | Treatment With Pirfenidone for COVID-19 Related Severe ARDS | Recruiting | Covid19 ARDS | Drug: Pirfenidone Other: Standard of care | N/A | Soroka University Medical Center |
NCT04356833 | Nebulised Rt-PA for ARDS Due to COVID-19 (PACA) | Recruiting | Covid19 ARDS | Drug: nebulised (rt-PA) | 2 | University College, London |
NCT04453371 | Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) (AtTAC) | Withdrawn | Covid19 ARDS | Drug: Tissue plasminogen activator Drug: Ringer solution | 3 | Negovsky Reanimatology Research Institute |
NCT04357730 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | Active, not recruiting | Covid19 ARDS | Drug: Alteplase 50 MG [Activase] | 2 | Denver Health and Hospital Authority |
NCT04530578 | Severe Acute Respiratory Syndrome Respiratory Failure Acute Respiratory Distress Syndrome | Recruiting | Covid19 Pneumonia | Drug: Heparin sodium Drug: Enoxaparin | 4 | Clinica San Camilo, Argentina |
NCT04350580 | Polyvalent Immunoglobulin in COVID-19 Related ARds (ICAR) | Completed | Covid19 ARDS | Drug: Human immunoglobulin Drug: Placebo | 3 | Centre Hospitalier St Anne |
NCT04261426 | The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia | Not yet recruiting | Covid19 | Drug: Intravenous Immunoglobulin Other: Standard care | 2 3 | Peking Union Medical College Hospital |
NCT04380935 | Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome | Recruiting | Covid19 ARDS | Biological: Convalescent plasma Drug: Standard of care | 2 3 | Indonesia University |
NCT04382755 | Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure (ZILU-COV) | Active, not recruiting | COVID-19 | Drug: Zilucoplan® Drug: Placebo | 2 | University Hospital, Ghent |
NCT04320277 | Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) | Not yet recruiting | Pharmacological Action | Drug: Baricitinib | 2 3 | Hospital of Prato |
NCT04359290 | Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil) | Active, not recruiting | Covid19 ARDS | Drug: Ruxolitinib administration | 2 | Philipps University Marburg Medical Center |
NCT04322773 | Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (TOCIVID) | terminated (The study has been terminated due to changed clinical conditions and too few patients available) | Covid19 | Drug: RoActemra iv Drug: RoActemra sc Drug: Kevzara sc Other: Standard medical care | 2 | Marius Henriksen |
NCT04320615 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) | Completed | COVID-19 Pneumonia | Drug: Tocilizumab (TCZ) Drug: Placebo | 3 | Hoffmann-La Roche |
NCT04466098 | Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) | Active, not recruiting | Covid19 ARDS | Biological: Mesenchymal stromal cells Other: Placebo | 2 | Masonic Cancer Center, University of Minnesota |
NCT04416139 | Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 (COVID-19) | Recruiting | Covid19 ARDS | Biological: Infusion IV of Mesenchymal Stem cells | 2 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
NCT04327401 | COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III (CoDEX) | Terminated (The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial results, which was accepted by the CoDEX Steering Committee.) | Covid19 ARDS | Drug: Dexamethasone | 3 | Hospital Sirio-Libanes |
NCT04244591 | Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure | Completed | Covid19 | Drug: methylprednisolone therapy Other: Standard care | 2 3 | Peking Union Medical College Hospital |
NCT04337190 | Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2) | Recruiting | Covid19 ARDS | Biological: blood sampling | – | University Hospital, Angers |
NCT04328012 | COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED) | Recruiting | Covid19 | Drug: lopinavir/ritonavir Drug: Losartan Drug: Placebos | 2 3 | Bassett Healthcare |
NCT04321096 | The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19) | Recruiting | Covid19 | Drug: Camostat Mesilate Drug: Placebo oral tablet | 1 2 | University of Aarhus |
NCT04328493 | The Vietnam Chloroquine Treatment on COVID-19 (VICO) | Completed | Covid19 | Drug: Chloroquine phosphate | 2 | Oxford University Clinical Research Unit, Vietnam |
NCT04475991 | Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults (COMVIVIR) | Not yet recruiting | Covid19 | Drug: Maraviroc + Currently used therapy Procedure: Curently used therapy for COVID-19 non-critical patients Drug: Favipiravir + Currently used therapy Drug: Maraviroc+Favipiravir+CT | 2 | Hospital General de México Dr. Eduardo Liceaga |
NCT04307693 | Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) | Terminated (Terminated early because no patients were further enrolled since mid-Apr 2020.) | Covid19 | Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine sulfate | 2 | Asan Medical Center |